This database contains 202 studies, archived under the term: "drug effects"
Click here to filter this large number of results.
Saffron in the treatment of patients with mild to moderate Alzheimer’s disease: a 16-week, randomized and placebo-controlled trial
Akhondzadeh, S.,
Sabet, M. Shafiee,
Harirchian, M. H.,
Togha, M.,
Cheraghmakani, H.,
Razeghi, S.,
Hejazi, S. Sh,
Yousefi, M. H.,
Alimardani, R.,
Jamshidi, A.,
Zare, F.,
Moradi, A.
What Is Known: Herbal medicines have been used in the treatment of behavioural and psychological symptoms of dementia but with variable response. Crocus sativus (saffron) may inhibit the aggregation and deposition of amyloid β in the human brain and may therefore be useful in Alzheimer’s disease (AD).; Objective: The goal of this study was to […]
Controlled study of auricular point taping and pressing therapy for treatment of vascular dementia
Chen, Qi,
Huang, Hong-min,
Xu, Yu-jiao,
Lu, Rui-li,
Zhou, Xiao-hui,
Zhou, Cheng
Objective: To assess the therapeutic effect of auricular point taping and pressing therapy on vascular dementia (VD).; Methods: One hundred and eighty cases of vascular dementia were randomly divided into an auricular point taping and pressing group and a western medicine group, 90 cases in each group. The auricular point taping and pressing group was […]
Postmenopausal hormone therapy and subclinical cerebrovascular disease: the WHIMS-MRI Study
Coker, L. H.,
Hogan, P. E.,
Bryan, N. R.,
Kuller, L. H.,
Margolis, K. L.,
Bettermann, K.,
Wallace, R. B.,
Lao, Z.,
Freeman, R.,
Stefanick, M. L.,
Shumaker, S. A.
Objective: The Women’s Health Initiative Memory Study (WHIMS) hormone therapy (HT) trials reported that conjugated equine estrogen (CEE) with or without medroxyprogesterone acetate (MPA) increases risk for all-cause dementia and global cognitive decline. WHIMS MRI measured subclinical cerebrovascular disease as a possible mechanism to explain cognitive decline reported in WHIMS.; Methods: We contacted 2,345 women […]
Ibuprofen treatment modifies cortical sources of EEG rhythms in mild Alzheimer’s disease
Babiloni, Claudio,
Frisoni, Giovanni B.,
Del Percio, Claudio,
Zanetti, Orazio,
Bonomini, Cristina,
Cassetta, Emanuele,
Pasqualetti, Patrizio,
Miniussi, Carlo,
De Rosas, Mario,
Valenzano, Anna,
Cibelli, Giuseppe,
Eusebi, Fabrizio,
Rossini, Paolo M.
Objective: Non-steroidal anti-inflammatory drugs such as ibuprofen have a protective role on risk of Alzheimer’s disease (AD). Here we evaluated the hypothesis that long-term ibuprofen treatment affects cortical sources of resting electroencephalographic (EEG) rhythms in mild AD patients.; Methods: Twenty-three AD patients (13 treated AD IBUPROFEN; 10 untreated AD PLACEBO) were enrolled. Resting EEG data […]
Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition
Espeland, Mark A.,
Shumaker, Sally A.,
Limacher, Marian,
Rapp, Stephen R.,
Bevers, Therese B.,
Barad, David H.,
Coker, Laura H.,
Gaussoin, Sarah A.,
Stefanick, Marcia L.,
Lane, Dorothy S.,
Maki, Pauline M.,
Resnick, Susan M.
Objective: To compare the relative effects of conjugated equine estrogens (CEE), raloxifene, and tamoxifen therapies on cognition among women aged > or =65 years.; Methods: Annual Modified Mini-Mental State (3MS) examinations were used to assess global cognitive function in the two randomized placebo-controlled clinical trials of CEE therapies of the Women’s Health Initiative Memory Study […]
Alzheimer’s Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results
Background: The Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT) was designed to address whether non-steroidal anti-inflammatory drugs (NSAIDs) can prevent or delay the onset of Alzheimer’s disease (AD).; Methods: ADAPT was a randomized, double-placebo-controlled, multicenter chemoprevention trial conducted at six U.S. dementia research clinics. At entry, participants were required to test “normal” on a battery of […]
Akatinol memantine in patients with vascular cognitive disorders
Treatment of cognitive disorders developed in cerebrovascular pathology is an actual medical problem. Of great importance is the timed diagnosis of these changes in the earlier phases of the development of cognitive deficit as well as adequate therapy that can delay and prevent the development of such complication as dementia. Pathogenetic mechanisms of cognitive disorders […]
Efficacy of acatinol memantine in mild cognitive disorder
An open 6 month clinical trial of efficacy of acatinol has been carried out in patients with mild cognitive disorder (MCD). Forty patients received acatinol and 20 patients of comparison group were treated with piracetam. Mean age of patients was 67,7+/-7,2 years. Patient’s state was assessed with a battery of scales, questionnaires and neuropsychological tests. […]
Galantamine (reminyl) in the treatment of severe Alzheimer’s disease
Twenty-five patients with Alzheimer’s disease (AD) in moderate-severe and severe stages received galantamine in dosage 8 mg daily during the 1st month with the following increasing to 16 mg daily. Six patients received 24 mg per day from the 3rd month. The total duration of therapy was 26 weeks. 15 patients received in addition the […]